thanks but the only bets I make are on Novavax. Regardless... I'll donate to the Salvation Army and hope you might do the same.
That's not a long time to wait. No doubt that the phase III RSV trials will succeed. Quad flu will be in the limelight and paired with RSV vaccine as a pure gold vaccine product. Few investments, if any, will rank with the quality of your Novavax shares. If Zika vaccine is developed the 3-6 factor will be highly conservative.
Buy... hold.... and wait. That's all you need do.
"We will develop the RSV vaccine first in the elderly and bring it to market in the US and plan to partner it outside of the US with global vaccine companies. So it's a large market. The RSV market is a large market. We think it's the biggest unmet need for a vaccine that exists right now. It carries a huge disease burden approaching $100 billion in the large developed countries but it's a global problem as well. And we are developing the product particularly for pediatric -- to protect newborns by vaccinating pregnant women globally. So what we'll talked about is the three target markets. In older adults there are over 2.5 million annual infections in the US. Maternal immunizations -- 1.4 million infants contract RSV and as I mentioned before very large market her disease burden. And we'll develop both these vaccines in Phase III -- so over the next year or two"
as of Feb 2nd
"Where is the Zika Virus Found and How is it Transmitted?
Zika virus was first isolated from monkeys in the Zika Forest in Uganda in 1947, but it was not considered an important cause of disease in humans until the first large-scale outbreaks appeared in the South Pacific islands in 2007. By March 2014, tourists were believed to have carried Zika virus to Easter Island, about 2,180 miles west of continental Chile. In May 2015, local transmission was first reported in South America, then in Central America, and then in the Caribbean, finally reaching Mexico by late November 2015.
Currently, ongoing local transmission of Zika virus has been reported in: 1 North American country (Mexico); 9 South American countries (Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Suriname, and Venezuela); 6 Central American countries (Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama); and 9 Caribbean islands (Barbados, Curacao, Dominican Republic, Guadeloupe, Haiti, Martinique, the Commonwealth of Puerto Rico, Saint Martin, and the U.S. Virgin Islands), for which the US Centers for Disease Control and Prevention (CDC) has issued travel alerts. Also, the CDC has issued a travel alert for Cape Verde, a nation of islands off the northwest coast of Africa, and one for Samoa and American Samoa."
true... NVAX can carry the ball to and through a preclinic and phase I... by then WHO or BARDA or B&M Gates and others should help pay trial costs... fug the congress... we don't need them. NVAX knows what they are doing... I hope the development is going well for them...Zika is not flu.
"Attempts to develop an RSV vaccine have been stymied despite 60 years of research by vaccinologists. Our scientific breakthrough in the development of an RSV nanoparticle vaccine candidate and our rapid advances in clinical development are excellent examples of the power of our technology.
Genetic Engineering in Insect Cells
We produce our vaccine nanoparticles in cells originally isolated in the 1970s from the ovaries of the fall armyworm (Spodoptera frugiperda). In the early 1980s, scientists at Texas A&M (Smith, et al. 1983) discovered that one of these "Sf" insect cell lines, Sf9, could grow in apparent perpetuity in a special culture medium and could be made to produce recombinant proteins by infecting them with a baculovirus (BV), a virus that infects only insects. Because a baculovirus can be engineered to carry one or more foreign genes of interest, it can be used to "program" (infect) the Sf9 cells to efficiently produce the desired protein or proteins that, unlike simple bacteria or yeast-cell expression technology, are correctly folded and biologically active when made in these more highly evolved insect cell lines. Novavax uses the Sf9 system to construct two types of immunogenic nanoparticles that form the basis of our vaccine candidates:
Recombinant protein nanoparticles that are tailored toward a single type of recombinant protein, and;
Virus-like particles (or VLPs), which enable the incorporation of multiple antigens onto a single /download/images/vaccine/rsv.pngparticle.
Recombinant Protein Nanoparticles
Our RSV vaccine candidate illustrates how Novavax scientists use our Sf9/baculovirus recombinant technology platform to create new product candidates."
A Zika vaccine will be highly valuable to humanity, as things are shaping up. These long term maladies are long term costly. Zika is surely spreading at a threatening and accelerating rate. If Novavax succeeds in its development of a vaccine, they could also be on the path to a dengue vaccine. A 2-fer. I trust we'll learn more from Erck/Glenn on these matters in the CC next week.
Warren Buffett has a simple explanation for why rich Americans should pay higher taxes
"If you’re in the luckiest 1% of humanity, you owe it to the rest of humanity to think about the other 99%."
I look at the volatility of share price, daily, monthly, ... as determined by two forces. I need this simplistic formula to view the future.
1. The basic condition of the company. Pipeline status, vaccine platform, RSV trial progress, management prowess, employees, finances available for growth, trials, marketing, production, facility, partnering... and so forth.
2. The hodgepodge of outside control.... funds... hedgers, options, conversions, shorts, manipulators, and so forth.
My knowledge of number 2 is very, very superficial... I have a handle and faith in number 1. and base my investment on that alone, with the expectation that number 1. will be the eventual winner, and will overcome the number 2. nuisance. Number 1. is the body and flesh of Novavax company. Number 2. has a daily effect but is a parasite that will be eschewed by the dominant force of number 1....
The basic condition of the company is powerful and enduring, and just cannot be overcome by the game players of number 2. The sky will not fall, doubters.
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016
GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Wednesday, May 4, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities.